IRIS
TAGLIAFERRI, PIEROSANDRO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 5.644
AS - Asia 4.777
EU - Europa 2.383
SA - Sud America 1.194
AF - Africa 111
Continente sconosciuto - Info sul continente non disponibili 25
OC - Oceania 21
Totale 14.155
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 5.341
SG - Singapore 2.189
IT - Italia 1.068
CN - Cina 1.029
BR - Brasile 925
IN - India 550
VN - Vietnam 539
SE - Svezia 332
GB - Regno Unito 312
DE - Germania 254
CA - Canada 227
AR - Argentina 98
FI - Finlandia 91
ID - Indonesia 76
HK - Hong Kong 71
BD - Bangladesh 59
NL - Olanda 54
EC - Ecuador 50
RU - Federazione Russa 46
MX - Messico 45
ZA - Sudafrica 40
IQ - Iraq 35
PK - Pakistan 34
UA - Ucraina 33
CO - Colombia 32
JP - Giappone 31
ES - Italia 30
FR - Francia 28
JO - Giordania 28
PY - Paraguay 28
RO - Romania 28
EU - Europa 22
TR - Turchia 21
PL - Polonia 20
CL - Cile 19
EG - Egitto 18
IR - Iran 17
SA - Arabia Saudita 17
VE - Venezuela 17
AT - Austria 15
AU - Australia 15
PE - Perù 14
CZ - Repubblica Ceca 13
AE - Emirati Arabi Uniti 12
KE - Kenya 11
LT - Lituania 11
MA - Marocco 11
PT - Portogallo 9
TN - Tunisia 9
EE - Estonia 8
NG - Nigeria 8
LB - Libano 7
MY - Malesia 7
UY - Uruguay 7
UZ - Uzbekistan 7
BG - Bulgaria 6
ET - Etiopia 6
GT - Guatemala 6
IE - Irlanda 6
KR - Corea 6
HN - Honduras 5
NP - Nepal 5
CH - Svizzera 4
CU - Cuba 4
CY - Cipro 4
DO - Repubblica Dominicana 4
NZ - Nuova Zelanda 4
PH - Filippine 4
TW - Taiwan 4
AL - Albania 3
AZ - Azerbaigian 3
DZ - Algeria 3
IL - Israele 3
LK - Sri Lanka 3
PA - Panama 3
TT - Trinidad e Tobago 3
A2 - ???statistics.table.value.countryCode.A2??? 2
BA - Bosnia-Erzegovina 2
BN - Brunei Darussalam 2
BO - Bolivia 2
CR - Costa Rica 2
GE - Georgia 2
GY - Guiana 2
HR - Croazia 2
HU - Ungheria 2
KG - Kirghizistan 2
KI - Kiribati 2
KZ - Kazakistan 2
OM - Oman 2
PS - Palestinian Territory 2
SN - Senegal 2
TH - Thailandia 2
BE - Belgio 1
BY - Bielorussia 1
CV - Capo Verde 1
GM - Gambi 1
GR - Grecia 1
JM - Giamaica 1
KW - Kuwait 1
MD - Moldavia 1
Totale 14.147
Salva come PNG Salva come JPEG
Città #
Chandler 826
Singapore 694
Santa Clara 421
Hefei 398
Bengaluru 396
Dallas 378
Milan 362
Lawrence 351
Princeton 351
Chicago 244
Ashburn 241
London 215
Ho Chi Minh City 208
Munich 198
Wilmington 190
Ottawa 160
Beijing 159
Des Moines 118
Catanzaro 105
Hanoi 101
São Paulo 84
Turku 66
Boardman 62
Hong Kong 61
Los Angeles 61
New York 45
Shanghai 44
Rome 37
Pune 35
Rio de Janeiro 35
Norwalk 34
Naples 33
Guangzhou 31
San Francisco 29
Brooklyn 28
Council Bluffs 28
Redmond 28
Haiphong 27
Da Nang 26
Helsinki 25
The Dalles 24
Montreal 22
Redwood City 22
Tokyo 21
Warsaw 21
Amman 20
Curitiba 19
Thái Bình 19
Manchester 18
Chennai 17
Columbus 16
Dhaka 16
Parma 16
San Nicola Manfredi 16
Shenzhen 16
Stockholm 16
Atlanta 15
Biên Hòa 15
Johannesburg 15
Horia 14
Phoenix 14
Porto Alegre 14
Salvador 14
Baghdad 13
Guayaquil 13
Quito 13
Reggio Calabria 13
Seattle 13
Toronto 13
Augusta 12
Carbonia 12
Cosenza 12
Mexico City 12
Palermo 12
Spezzano della Sila 12
Belo Horizonte 11
Boston 11
Campinas 11
Cape Town 11
Hanover 11
Mountain View 11
Olomouc 11
Recife 11
Amsterdam 10
Ankara 10
Brasília 10
Delhi 10
Denver 10
Guarulhos 10
Jakarta 10
Manaus 10
Nairobi 10
Ninh Bình 10
Thái Nguyên 10
West Jordan 10
Buenos Aires 9
Jiaxing 9
Lima 9
Sorocaba 9
Afragola 8
Totale 7.737
Salva come PNG Salva come JPEG
Nome #
Pharmacogenetics/Pharmacogenomics of Drug-Metabolizing Enzymes and Transporters 406
A Novel Bispecific T-Cell Engager (CD1a x CD3ε) BTCE Is Effective against Cortical-Derived T Cell Acute Lymphoblastic Leukemia (T-ALL) Cells 118
Safety and activity of the first-in-class locked nucleic acid (LNA) miR-221 selective inhibitor in refractory advanced cancer patients: a first-in-human, phase 1, open-label, dose-escalation study 96
miR-22 suppresses DNA ligase III addiction in multiple myeloma 96
A drug repurposing screening reveals a novel epigenetic activity of hydroxychloroquine. 85
miR-221/222 as biomarkers and targets for therapeutic intervention on cancer and other diseases: A systematic review 79
Distinctive germline expression of class i human leukocyte antigen (HLA) alleles and DRB1 heterozygosis predict the outcome of patients with non-small cell lung cancer receiving PD-1/PD-L1 immune checkpoint blockade 78
MiR-29b antagonizes the pro-inflammatory tumor-promoting activity of multiple myeloma-educated dendritic cells 73
A 13 mer LNA-i-miR-221 Inhibitor Restores Drug Sensitivity in Melphalan-Refractory Multiple Myeloma Cells 72
A p53-dependent tumor suppressor network is induced by selective miR-125a-5p inhibition in multiple myeloma cells in vitro 71
Raman Spectroscopic Stratification of Multiple Myeloma Patients Based on Exosome Profiling 70
Identification of polymorphic variants associated with erlotinib-related skin toxicity in advanced non-small cell lung cancer patients by DMET microarray analysis 69
A Pronectin™ AXL-targeted first-in-class bispecific T cell engager (pAXLxCD3ε) for ovarian cancer 68
Non-coding RNAs in cancer: Platforms and strategies for investigating the genomic "dark matter" 68
Differential expression of UN1, early thymocyte-associated sialoglycoprotein, in breast normal tissue, benign disease and carcinomas 67
DMET-Analyzer: automatic analysis of Affymetrix DMET Data 67
Therapeutic afucosylated monoclonal antibody and bispecific T-cell engagers for T-cell acute lymphoblastic leukemia 64
Differential sensitivity of BRCA1-mutated HCC1937 human breast cancer cells to microtubule-interfering agents 63
LNA-Gapmer Antisense Oligonucleotides Targeting the Oncogenic Lncrna MALAT1 Trigger Anti-Multiple Myeloma Activity By Proteasome Blockade 63
HLA Expression Correlates to the Risk of Immune Checkpoint Inhibitor-Induced Pneumonitis 63
Safety and activity of the first-in-class locked nucleic acid (LNA) miR-221 selective inhibitor in refractory advanced cancer patients: a first-in-human, phase 1, open-label, dose-escalation study 62
Error-prone DNA repair pathways as determinants of immunotherapy activity: an emerging scenario for cancer treatment 60
Aurora Kinase A expression predicts platinum-resistance and adverse outcome in high-grade serous ovarian carcinoma patients 60
MiR-34a Replacement As a Novel Therapeutic Approach for Multiple Myeloma: Preclinical In Vitro and In Vivo Evidence 59
Whole gene expression profiling shows a differential transcriptional response to CISPLATINUM in BRCA-1 defective versus BRCA1-reconstituted breast cancer cells 58
A peroxisome proliferator-activated receptor gamma (PPARG) polymorphism is associated with zoledronic acid-related osteonecrosis of the jaw in multiple myeloma patients: analysis by DMET microarray profiling 58
MYC-MIR-22 REGULATORY LOOP MODULATES LENALIDOMIDE ACTIVITY IN MULTIPLE MYELOMA CELLS 58
miR-21 antagonism abrogates Th17 tumor promoting functions in multiple myeloma 58
A Prognostic and Carboplatin Response Predictive Model in Ovarian Cancer: A Mono-Institutional Retrospective Study Based on Clinics and Pharmacogenomics 57
Trabectedin triggers direct and NK-mediated cytotoxicity in multiple myeloma. (CO-FIRST AUTHOR) 57
The First-In-Class Anti-AXL×CD3ε Pronectin™-Based Bispecific T-Cell Engager Is Active in Preclinical Models of Human Soft Tissue and Bone Sarcomas 56
Fetal ontogeny and tumor expression of the early thymic antigen UN1 56
MIR-21 SUPPRESSION IMPAIRS TH17 RELATED BONE DISEASE IN MULTIPLE MYELOMA 56
Identifying prognostic markers for multiple myeloma through integration and analysis of MMRF-CoMMpass data 56
Autoimmune colitis and neutropenia in adjuvant anti-PD-1 therapy for malignant melanoma: efficacy of Vedolizumab, a case report 56
Aurora Kinase A expression predicts platinum-resistance and adverse outcome in high-grade serous ovarian carcinoma patients 55
miR-221/222 inhibitors for the treatment of multiple myeloma 55
Anti-tumor Activity and Epigenetic Impact of the Polyphenol Oleacein in Multiple Myeloma 54
Exploiting DNA Ligase III addiction of multiple myeloma by flavonoid Rhamnetin 53
Mir-34: a new weapon against cancer? 53
A gene expression inflammatory signature specifically predicts multiple myeloma evolution and patients survival 53
Impact of natural dietary agents on multiple myeloma prevention and treatment: molecular insights and potential for clinical translation. 53
MicroRNAs: Novel Crossroads between Myeloma Cells and the Bone Marrow Microenvironment 53
Exploiting MYC-induced PARPness to target genomic instability in multiple myeloma 53
ACTIVATION OF GPER SIGNALING AS A POTENTIAL THERAPEUTIC STRATEGY AGAINST WALDENSTROM MACROGLOBULINEMIA 53
Anti-myeloma activity of miR-125 mimics 53
Chromene Derivatives as Selective TERRA G-Quadruplex RNA Binders with Antiproliferative Properties 52
Synergistic antitumor activity of epidermal growth factor receptor tyrosine kinase inhibitor gefitinib and IFN-alpha in head and neck cancer cells in vitro and in vivo 52
PEGylated Aqueous core PLA-nanocapsules as efficacious gene delivery vehicle 52
Allometric scaling approaches for predicting human pharmacokinetic of a locked nucleic acid oligonucleotide targeting cancer-associated miR-221 52
Pharmacogenomics biomarker discovery and validation for translation in clinical practice. 52
CARDIOVASCULAR MONITORING OF DRUG-RESISTANT LYMPHOMA PATIENTS TREATED WITH EPOCH CHEMOTHERAPY PLUS HIGH-DOSE VERAPAMIL IN CONTINUOUS-INFUSION 51
Selective Activation of the Non-Classical Estrogen Receptor Gper Elicits Potent Anti-Tumor Activity in Multiple Myeloma 51
Anti-MALAT1 synthetic oligonucleotides target the proteasome and exert anti-multiple myeloma activity 51
Inhibition of EZH2 triggers the tumor suppressive miR-29b network in multiple myeloma 50
A systematic review and meta-analysis of randomized trials on the role of targeted therapy in the management of advanced gastric cancer: Evidence does not translate? 50
Influence of the fabrication accuracy of hot-embossed PCL scaffolds on cell growths 50
DMET-miner: Efficient learning of association rules from genotyping data for personalized medicine 50
2 CLASSES OF CAMP ANALOGS SYNERGISTICALLY INHIBIT P21 RAS PROTEIN-SYNTHESIS AND PHENOTYPIC TRANSFORMATION OF NIH/3T3 CELLS TRANSFECTED WITH HA-MUSV DNA 49
Protein arginine methyltransferase 5 has prognostic relevance and is a druggable target in multiple myeloma. 49
Early blood rise in auto-antibodies to nuclear and smooth muscle antigens is predictive of prolonged survival and autoimmunity in metastatic-non-small cell lung cancer patients treated with PD-1 immune-check point blockade by nivolumab 49
A p53-dependent tumor suppressor network is induced by selective miR-125a-5p inhibition in multiple myeloma cells 49
Targeting of multiple myeloma-related angiogenesis by miR-199a-5p mimics: In vitro and in vivo anti-tumor activity 48
BRCA1 expression modulates chemosensitivity of BRCA1-defective HCC1937 human breast cancer cells 48
BRCA1 expression modulates chemosensitivity of BRCA1-defective HCC1937 human breast cancer cellsBritish Journal of cancer 48
Polymorphic variants in NR1I3 and UGT2B7 predict taxane neurotoxicity and have prognostic relevance in breast cancer patients: a case-control study. 48
A combination of gefitinib and FOLFOX-4 as first-line treatment in advanced colorectal cancer patients. A GISCAD multicentre phase II study including a biological analysis of EGFR overexpression, amplification and NF-kB activation 48
Non-coding RNA: A novel opportunity for the personalized treatment of multiple myeloma 48
BRCA1/2 molecular assay for ovarian cancer patients: A survey through Italian departments of oncology and molecular and genomic diagnostic laboratories 48
Activation of the Non-Canonical Estrogen Receptor Gper As a Novel Therapeutic Strategy Against Waldenstrom Macroglobulinemia 48
Pharmacokinetics and Pharmacodynamics of a 13-mer LNA-inhibitor-miR-221 in Mice and Non-human Primates 48
Mir-22 modulates lenalidomide activity by counteracting myc addiction in multiple myeloma 48
TERRA G-quadruplex stabilization as a new therapeutic strategy for multiple myeloma 47
Mir-221/222 are promising targets for innovative anticancer therapy 47
5-AZA-2'-DEOXYCYTIDINE INDUCES GROWTH-INHIBITION AND UP-REGULATION OF EPIDERMAL GROWTH-FACTOR RECEPTOR ON HUMAN EPITHELIAL CANCER-CELLS 47
A unique three-dimensional SCID-polymeric scaffold (SCID-synth-hu) model for in vivo expansion of human primary multiple myeloma cells 47
Daily low-dose subcutaneous recombinant interleukin-2 by alternate weekly administration - Antitumor activity and immunomodulatory effects 47
A retrospective analysis of pegylated liposomal doxorubicin in ovarian cancer: do we still need it? 47
DmetTM genotyping: Tools for biomarkers discovery in the era of precision medicine 47
Drugging the lncRNA MALAT1 via LNA gapmeR ASO inhibits gene expression of proteasome subunits and triggers anti-multiple myeloma activity. 46
COOPERATIVE ANTIPROLIFERATIVE EFFECTS OF 8-CHLORO-CYCLIC AMP AND 528 ANTIEPIDERMAL GROWTH-FACTOR RECEPTOR MONOCLONAL-ANTIBODY ON HUMAN CANCER-CELLS 46
In Vivo Activity of MiR-34a Mimics Delivered by Stable Nucleic Acid Lipid Particles (SNALPs) against Multiple Myeloma 46
Editorial: New approaches in the treatment of multiple myeloma: from target-based agents to the new era of microRNAs (dedicated to the memory of Prof. Salvatore Venuta) 46
Inibitore LNA-miR-221 per il trattamento dei tumori 46
GOLFIG Chemo-Immunotherapy in Metastatic Colorectal Cancer Patients. A Critical Review on a Long-Lasting Follow-Up 46
miR-125b Upregulates miR-34a and Sequentially Activates Stress Adaption and Cell Death Mechanisms in Multiple Myeloma 46
Modeling UGT2B7 and NR1I3 genes through multilayer network to highlight hidden link with taxane neurotoxicity 45
A PH-DEPENDENT DIFFERENTIAL CYTO-TOXICITY OF OUABAIN FOR HUMAN-CELLS TRANSFORMED BY CERTAIN ONCOGENES 45
Canonical and noncanonical Hedgehog pathway in the pathogenesis of multiple myeloma 45
Cytotoxic drugs up-regulate epidermal growth factor receptor (EGFR) expression in colon cancer cells and enhance their susceptibility to EGFR-targeted antibody-dependent cell-mediated-cytotoxicity (ADCC) 45
A35 SINGLE NUCLEOTIDE POLYMORPHISMS OF THE ABCG1 AND ABCC5 TRANSPORTER GENES CORRELATE TO IRINOTECAN-ASSOCIATED GASTROINTESTINAL TOXICITY IN COLORECTAL CANCER PATIENTS AS ASSESSED BY DMET MICROARRAY PROFILING 45
Familial papillary thyroid microcarcinoma: a new clinical entity 45
Dose-Finding Study and Pharmacokinetics Profile of the Novel 13-Mer Antisense miR-221 Inhibitor in Sprague-Dawley Rats 45
Proteomic profiling of inherited breast cancer: Identification of molecular targets for early detection, prognosis and treatment, and related bioinformatics tools 45
Gut Microbiota Are a Novel Source of Biomarkers for Immunotherapy in Non-Small-Cell Lung Cancer (NSCLC) 44
The New Microtubule-Targeting Agent SIX2G Induces Immunogenic Cell Death in Multiple Myeloma 44
Replacement of miR-155 Elicits Tumor Suppressive Activity and Antagonizes Bortezomib Resistance in Multiple Myeloma. 44
Pharmacogenomic Profiling of ADME Gene Variants: Current Challenges and Validation Perspectives 44
In Vitro and in Vivo Anti-tumor Activity of miR-221/222 Inhibitors in Multiple Myeloma 44
Analysis of miRNA, mRNA, and TF interactions through network-based methods 44
Totale 5.855
Salva come PNG Salva come JPEG
Categoria #
all - tutte 166.075
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 166.075
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021251 0 0 0 0 0 32 33 19 48 69 44 6
2021/2022979 19 6 12 286 57 19 31 202 96 92 146 13
2022/20232.607 722 77 85 210 279 230 13 167 395 162 217 50
2023/20241.366 311 135 116 94 98 321 41 53 15 48 61 73
2024/20254.168 563 250 184 127 234 521 108 155 486 267 423 850
2025/20264.658 412 897 819 1.510 850 170 0 0 0 0 0 0
Totale 14.448